Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

REDLAMP 13: How Are Outcomes Improving for Patients with Transformed Follicular Lymphoma?

The diagnosis for follicular lymphoma that has transformed into diffuse large B-cell lymphoma (DLBCL) has in the past been associated with a poor prognosis for patients. However, in a National LymphoCare Study recently published in Blood, researchers assessed the incidence, prognostic features, and outcomes associated with the transformation of follicular lymphoma in enrolled patients. In this video Dr. John Leonard discusses the findings of the study. Specifically reviewed are new data on outcomes, based on novel approaches and therapies for patients whose follicular lymphoma has transformed.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.

Dr. Richard Furman Discusses Recent Chronic Lymphocytic Leukemia Research Highlights

In this video from Patient Power, CLL Program Director, Dr. Richard Furman discusses recent results on chronic lymphocytic leukemia (CLL) presented in abstracts during the 2015 meeting of the American Society of Hematology (ASH) and the place of newly targeted therapies including ABT-199 and ACP-196 in treating patients with CLL.

Dr. Furman has previously written about CLL abstracts from the 2015 ASH meeting here and here. More information about available CLL trials at Weill Cornell Medicine can be found on the Joint Clinical Trials website.

Ibrutinib—A New Standard Treatment for Mantle Cell Lymphoma?

In The Lancet, Dr. Peter Martin commented on the results of a recently completed phase 3 trial in Europe that compared ibrutinib to temsirolimus among patients with mantle cell lymphoma. He writes that the results of the study clearly establish, “…ibrutinib as a new standard for treatment of relapsed mantle cell lymphoma.” Dr. Martin’s full comments on the topic can be found in the attached PDF below:

Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?

A full listing of currently available clinical trials for mantle cell lymphoma can be found on the Joint Clinical Trials website.